Clinical Trial Update: Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing oral paclitaxel with encequidar to standard IV paclitaxel for HER2-negative metastatic breast cancer, with recruitment not yet started…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Encequidar (encequidar)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Health Hope Pharma | Conditions: Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING